ArticleArteriosclerosis, thrombosis, and vascular biology2026
Empagliflozin Improves Angina and Endothelial Dysfunction Indices in Angina and No Obstructive Coronary Arteries (ANOCA).
Article in Arteriosclerosis, thrombosis, and vascular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundTreatments targeting endothelial dysfunction in patients with angina and no obstructive coronary arteries (ANOCA) and coronary microvascular and vasomotor dysfunction (CMVD) are lacking. We evaluated the effects of SGLT2i (sodium-glucose cotransporter-2 inhibition) on angina, inflammatory and oxidative stress biomarkers, and endothelial dysfunction indices using a serum-induced in vitro model in ANOCA patients with CMVD. We conducted an open-label pilot trial of 11 ANOCA participants with CMVD diagnosed by invasive coronary function testing receiving empagliflozin (10 mg daily) for 90 days.
methodsAngina (Seattle Angina Questionnaire), circulating inflammatory and oxidative stress biomarkers, and endothelial microvesicles (eEVs) were assessed from baseline to 45 and 90 days, and from 90 days to posttreatment discontinuation in a subset (N=5). A serum-induced in vitro model of human coronary artery endothelial cells was used to evaluate endothelial cell apoptosis, viability, eEV release, VCAM-1 (vascular cell adhesion molecule-1) expression, and mitochondrial reactive oxygen species. Stored serum from ANOCA patients without CMVD (controls, N=6) was compared with baseline samples.
resultsAll trial participants had coronary endothelial dysfunction, with concomitant coronary microvascular dysfunction (55%), coronary spasm (54%), and microvascular spasm (18%). Empagliflozin significantly improved Seattle Angina Questionnaire summary scores by 14.0 (4.2-23.9) points at 90 days (
conclusionsIn ANOCA participants with invasive coronary function testing confirmed CMVD, SGLT2i therapy produced clinically meaningful anti-anginal effects and reversed multiple indices of endothelial dysfunction, with rebound after treatment discontinuation. These findings support further evaluation in larger clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.